Udai S. Kammula

Udai S. Kammula

Surgical Oncology

5115 Centre Avenue, Hillman Cancer Center
Pittsburgh, PA 15232

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

ASO Visual Abstract: Liver Metastasectomy to Obtain Tumor-Infiltrating Lymphocytes: Technical Considerations and Report on Single-Center Experience.

ASO Visual Abstract: Liver Metastasectomy to Obtain Tumor-Infiltrating Lymphocytes: Technical Considerations and Report on Single-Center Experience.

Journal: Annals of surgical oncology

Published: June 03, 2026

The lncRNA EPIC1 suppresses dsRNA-induced type I IFN signaling and is a therapeutic target to enhance TNBC response to PD-1 inhibition.

The lncRNA EPIC1 suppresses dsRNA-induced type I IFN signaling and is a therapeutic target to enhance TNBC response to PD-1 inhibition.

Journal: Science signaling

Published: August 12, 2025

Liver Metastasectomy to Obtain Tumor-Infiltrating Lymphocytes: Technical Considerations and Report on Single-Center Experience.

Liver Metastasectomy to Obtain Tumor-Infiltrating Lymphocytes: Technical Considerations and Report on Single-Center Experience.

Journal: Annals of surgical oncology

Published: July 14, 2025

The T cell receptor landscape of childhood brain tumors.

The T cell receptor landscape of childhood brain tumors.

Journal: Science translational medicine

Published: March 19, 2025

Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma.

Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma.

Journal: Immunotherapy

Published: March 18, 2025

Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility.

Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility.

Journal: Nature communications

Published: June 20, 2023

Genome-wide gain-of-function screening characterized lncRNA regulators for tumor immune response.

Genome-wide gain-of-function screening characterized lncRNA regulators for tumor immune response.

Journal: Science advances

Published: December 08, 2022

In Vivo Priming of Peritoneal Tumor-Reactive Lymphocytes With a Potent Oncolytic Virus for Adoptive Cell Therapy.

In Vivo Priming of Peritoneal Tumor-Reactive Lymphocytes With a Potent Oncolytic Virus for Adoptive Cell Therapy.

Journal: Frontiers in immunology

Published: September 24, 2020

Characteristics of Malignant Pleural Effusion Resident CD8+ T Cells from a Heterogeneous Collection of Tumors.

Characteristics of Malignant Pleural Effusion Resident CD8+ T Cells from a Heterogeneous Collection of Tumors.

Journal: International journal of molecular sciences

Published: July 20, 2020

LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance.

LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance.

Journal: Science advances

Published: February 18, 2020

Cytologic Evaluation of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.

Cytologic Evaluation of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.

Journal: American journal of clinical pathology

Published: January 03, 2020

Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy.

Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy.

Journal: Cancer gene therapy

Published: December 09, 2019

Showing 1-12 of 44

Last Updated: 09/26/2026